BACKGROUND: Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART). METHODS: Nevirapine-exposed children who achieved virologic suppression with lopinavir/ritonavir-based induction HAART before switch to nevirapine-based HAART or who continued the lopinavir/ritonavir regimen were studied. Nevirapine-resistant HIV was quantified (≥ 1% frequency) in plasma before therapy and archived in peripheral blood mononuclear cells after induction HAART with ultradeep pyrosequencing. The primary endpoint was virologic failure (confirmed viremia ≥ 1000 copies/mL by 52 weeks) on nevirapine-based HAART, and Receiver operating characteristic analysis identified threshold levels of resistance associated with failure. RESULTS: Nevirapine resistance mutations were detected in plasma at a median frequency of 25.6% in 41 (33%) of 124 children starting HAART at median 9 months of age. After a median nine months of induction HAART, nevirapine-resistant HIV remained archived in cells in 59 (61%) of 96 children (median 13.6% of cells). The threshold frequency of nevirapine resistance in plasma most predictive of virologic failure on nevirapine-based HAART was 25%. Children maintaining resistance before therapy at or above this threshold frequency had a 3.5 fold higher risk of failure (95% confidence interval, 1.1-10.8) than children without detectable plasma resistance. In contrast, virologic failure was not independently associated with age, resistance in plasma below 25% frequencies, or archived in cells. CONCLUSIONS: Virologic suppression with lopinavir/ritonavir-based HAART in nevirapine-exposed children raises the threshold level of resistance at which reuse of nevirapine-based therapy is compromised. Standard genotyping may allow identification of children likely to benefit from an induction-switch approach.
BACKGROUND:Nevirapine resistance after failed prophylaxis to prevent mother-to-childhuman immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART). METHODS:Nevirapine-exposed children who achieved virologic suppression with lopinavir/ritonavir-based induction HAART before switch to nevirapine-based HAART or who continued the lopinavir/ritonavir regimen were studied. Nevirapine-resistant HIV was quantified (≥ 1% frequency) in plasma before therapy and archived in peripheral blood mononuclear cells after induction HAART with ultradeep pyrosequencing. The primary endpoint was virologic failure (confirmed viremia ≥ 1000 copies/mL by 52 weeks) on nevirapine-based HAART, and Receiver operating characteristic analysis identified threshold levels of resistance associated with failure. RESULTS:Nevirapine resistance mutations were detected in plasma at a median frequency of 25.6% in 41 (33%) of 124 children starting HAART at median 9 months of age. After a median nine months of induction HAART, nevirapine-resistant HIV remained archived in cells in 59 (61%) of 96 children (median 13.6% of cells). The threshold frequency of nevirapine resistance in plasma most predictive of virologic failure on nevirapine-based HAART was 25%. Children maintaining resistance before therapy at or above this threshold frequency had a 3.5 fold higher risk of failure (95% confidence interval, 1.1-10.8) than children without detectable plasma resistance. In contrast, virologic failure was not independently associated with age, resistance in plasma below 25% frequencies, or archived in cells. CONCLUSIONS: Virologic suppression with lopinavir/ritonavir-based HAART in nevirapine-exposed children raises the threshold level of resistance at which reuse of nevirapine-based therapy is compromised. Standard genotyping may allow identification of children likely to benefit from an induction-switch approach.
Authors: T W Chun; L Carruth; D Finzi; X Shen; J A DiGiuseppe; H Taylor; M Hermankova; K Chadwick; J Margolick; T C Quinn; Y H Kuo; R Brookmeyer; M A Zeiger; P Barditch-Crovo; R F Siliciano Journal: Nature Date: 1997-05-08 Impact factor: 49.962
Authors: Shahin Lockman; Roger L Shapiro; Laura M Smeaton; Carolyn Wester; Ibou Thior; Lisa Stevens; Fatima Chand; Joseph Makhema; Claire Moffat; Aida Asmelash; Patrick Ndase; Peter Arimi; Erik van Widenfelt; Loeto Mazhani; Vladimir Novitsky; Stephen Lagakos; Max Essex Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: S Palmer; V Boltz; N Martinson; F Maldarelli; G Gray; J McIntyre; J Mellors; L Morris; J Coffin Journal: Proc Natl Acad Sci U S A Date: 2006-04-25 Impact factor: 11.205
Authors: L A Guay; P Musoke; T Fleming; D Bagenda; M Allen; C Nakabiito; J Sherman; P Bakaki; C Ducar; M Deseyve; L Emel; M Mirochnick; M G Fowler; L Mofenson; P Miotti; K Dransfield; D Bray; F Mmiro; J B Jackson Journal: Lancet Date: 1999-09-04 Impact factor: 79.321
Authors: Tamara Flys; Dwight V Nissley; Cassidy W Claasen; Dana Jones; Chanjuan Shi; Laura A Guay; Philippa Musoke; Francis Mmiro; Jeffrey N Strathern; J Brooks Jackson; James R Eshleman; Susan H Eshleman Journal: J Infect Dis Date: 2005-06-01 Impact factor: 5.226
Authors: J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro Journal: Lancet Date: 2003-09-13 Impact factor: 79.321
Authors: Silvia Bertagnolio; Martina Penazzato; Michael R Jordan; Deborah Persaud; Lynne M Mofenson; Diane E Bennett Journal: Clin Infect Dis Date: 2012-05 Impact factor: 9.079
Authors: Jessica M Fogel; Anthony Mwatha; Paul Richardson; Elizabeth R Brown; Tsungai Chipato; Michel Alexandre; Dhayendre Moodley; Ali Elbireer; Mark Mirochnick; Kathleen George; Lynne M Mofenson; Sheryl Zwerski; Hoosen M Coovadia; Susan H Eshleman Journal: Pediatr Infect Dis J Date: 2013-04 Impact factor: 2.129